Wide Ranks

MNPR

Monopar Therapeutics Inc.

20.70

Top Statistics
Market Cap 109 M Forward PE -7.71 Revenue Growth 0.00 %
Current Ratio 6.59 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 7 M Total Cash Per Share 2.02 Total Debt
Total Debt To Equity Current Ratio 6.59 Book Value Per Share 1.88
All Measures
Short Ratio 15.00 % Message Board Id finmb_304391755 Shares Short Prior Month 652492
Return On Equity -1.02 City Wilmette Uuid 4c85e6c0-debc-355c-95b2-bf3324d36ecc
Previous Close 19.45 First Trade Date Epoch Utc 1 B Book Value 1.88
Beta 1.10 Volume 90565 Price To Book 11.04
Last Split Date 1 B Fifty Two Week Low 1.40 Total Cash Per Share 2.02
Shares Short Previous Month Date 1 B Target Median Price 23.00 Max Age 86400
Recommendation Mean 1.33 Sand P52 Week Change 0.3133 Target Mean Price 27.33
Net Income To Common -7124184 Short Percent Of Float 0.1022 Implied Shares Outstanding 5 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 94310
Average Volume10days 94310 Total Cash 7 M Next Fiscal Year End 1 B
Held Percent Insiders 0.4294 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 19.45 Target Low Price 22.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 11.67 Open 19.10
Free Cashflow -4433461 State IL Dividend Yield 0.00 %
Return On Assets -0.5344 Time Zone Short Name EST Trailing Eps -1.98
Day Low 18.81 Address1 1000 Skokie Boulevard Shares Outstanding 5 M
Price Hint 2 Target High Price 37.00 Website https://www.monopartx.com
52 Week Change 13.28 Average Volume 1 M Forward Eps -2.36
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Quick Ratio 653.40 %
Last Split Factor 1:5 Regular Market Day High 21.00 Is_sp_500 False
Profit Margins 0.00 % Fifty Two Week High 38.50 Day High 21.00
Shares Short 49852 Regular Market Open 19.10 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0142
Operating Cashflow -6817933 Currency USD Time Zone Full Name America/New_York
Market Cap 109 M Is_nasdaq_100 False Zip 60091
Quote Type EQUITY Industry Biotechnology Long Name Monopar Therapeutics Inc.
Regular Market Day Low 18.81 Held Percent Institutions 0.2447 Current Price 20.70
Address2 Suite 350 Financial Currency USD Current Ratio 6.59
Industry Disp Biotechnology Number Of Analyst Opinions 3 Country United States
Float Shares 1 M Two Hundred Day Average 5.51 Enterprise Value 48 M
Forward PE -7.71 Regular Market Volume 90565 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.

The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers.

It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers.

Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer.

The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Monopar Therapeutics Inc. is a subsidiary of Tacticgem LLC.